Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Interlaboratory study of free monoclonal immunoglobulin light chain quantification

Jaroslava Vávrová, Vladimír Maisnar, Miloš Tichý, Bedřich Friedecký, Zdeňka Čermáková, Milan Dastych, Jana Gottwaldová, Petr Kučera, Jarmila Krotká, Jaroslav Racek, Jana Ženková, Petr Schneiderka, Pavel Lochman, Tomáš Zima, Hana Benáková, Tomáš...

. 2011 ; 49 (1) : 89-92.

Jazyk angličtina Země Německo

Typ dokumentu srovnávací studie, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc12027946

Grantová podpora
NS10387 MZ0 CEP - Centrální evidence projektů
NS10406 MZ0 CEP - Centrální evidence projektů

BACKGROUND: Quantification of monoclonal immunoglobulin free light chains (FLCs) in serum is used increasingly in clinical practice for the diagnosis, prognostic assessment, and treatment monitoring of monoclonal gammopathies. It is used as an adjunct to standard serum protein electrophoresis and immunofixation. However, methods for FLC quantification need further standardization and validation. METHODS: The Czech Myeloma Group and the Czech Society of Clinical Biochemistry have initiated an interlaboratory study where six laboratories collaborating with the primary myeloma treatment centres measured FLC concentrations in 12 serum samples from patients with monoclonal gammopathies. RESULTS: Repeatability of the measurements in five laboratories was calculated based on differences between the results of duplicate measurements. We found that repeatability depended more on the laboratory than on the device used for measurement. CONCLUSIONS: The study revealed several weak points in the methodology, including the need for a uniform sample dilution procedure. Interlaboratory reproducibility was comparable with values achieved in the NEQAS programme. Because the κ/λ ratio cannot be measured with high precision, κ and λ FLC concentrations should be used where possible. Due to its impact on the clinical management of patients with gammopathy, FLC quantification needs to become a part of the regular quality control cycle in myeloma centres.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12027946
003      
CZ-PrNML
005      
20161013105731.0
007      
ta
008      
120817s2011 gw f 000 0#eng||
009      
AR
024    7_
$a 10.1515/cclm.2011.019 $2 doi
035    __
$a (PubMed)21034251
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Vávrová, Jaroslava $u Institute of Clinical Biochemistry and Diagnostics, Charles University Hospital, Hradec Kralove, Czech Republic
245    10
$a Interlaboratory study of free monoclonal immunoglobulin light chain quantification / $c Jaroslava Vávrová, Vladimír Maisnar, Miloš Tichý, Bedřich Friedecký, Zdeňka Čermáková, Milan Dastych, Jana Gottwaldová, Petr Kučera, Jarmila Krotká, Jaroslav Racek, Jana Ženková, Petr Schneiderka, Pavel Lochman, Tomáš Zima, Hana Benáková, Tomáš Büchler, Jana Spáčilová, Roman Hájek, Vladimír Palička
520    9_
$a BACKGROUND: Quantification of monoclonal immunoglobulin free light chains (FLCs) in serum is used increasingly in clinical practice for the diagnosis, prognostic assessment, and treatment monitoring of monoclonal gammopathies. It is used as an adjunct to standard serum protein electrophoresis and immunofixation. However, methods for FLC quantification need further standardization and validation. METHODS: The Czech Myeloma Group and the Czech Society of Clinical Biochemistry have initiated an interlaboratory study where six laboratories collaborating with the primary myeloma treatment centres measured FLC concentrations in 12 serum samples from patients with monoclonal gammopathies. RESULTS: Repeatability of the measurements in five laboratories was calculated based on differences between the results of duplicate measurements. We found that repeatability depended more on the laboratory than on the device used for measurement. CONCLUSIONS: The study revealed several weak points in the methodology, including the need for a uniform sample dilution procedure. Interlaboratory reproducibility was comparable with values achieved in the NEQAS programme. Because the κ/λ ratio cannot be measured with high precision, κ and λ FLC concentrations should be used where possible. Due to its impact on the clinical management of patients with gammopathy, FLC quantification needs to become a part of the regular quality control cycle in myeloma centres.
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a klinické laboratorní techniky $x metody $x normy $7 D019411
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a lehké řetězce imunoglobulinů $x analýza $x krev $7 D007147
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mnohočetný myelom $x krev $x diagnóza $7 D009101
650    _2
$a paraproteinemie $x krev $x diagnóza $7 D010265
650    _2
$a referenční standardy $7 D012015
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Maisnar, Vladimír $u Division of Clinical Haematology, 2nd Department of Medicine, Charles University Hospital, Hradec Kralove, Czech Republic; Czech Myeloma Group, Czech Republic
700    1_
$a Tichý, Miloš $u Institute of Clinical Biochemistry and Diagnostics, Charles University Hospital, Hradec Kralove, Czech Republic; Czech Myeloma Group, Czech Republic
700    1_
$a Friedecký, Bedřich $u Institute of Clinical Biochemistry and Diagnostics, Charles University Hospital, Hradec Kralove, Czech Republic
700    1_
$a Čermáková, Zdenka $u Department of Clinical Biochemistry and Haematology, Masaryk University Faculty of Medicine and University Hospital, Brno, Czech Republic
700    1_
$a Dastych, Milan $u Department of Clinical Biochemistry and Haematology, Masaryk University Faculty of Medicine and University Hospital, Brno, Czech Republic
700    1_
$a Gottwaldová, Jana $u Department of Clinical Biochemistry and Haematology, Masaryk University Faculty of Medicine and University Hospital, Brno, Czech Republic
700    1_
$a Kučera, Petr $u Department of Allergy and Clinical Immunology, Kralovske Vinohrady University Hospital, Prague, Czech Republic
700    1_
$a Krotká, Jarmila $u Department of Allergy and Clinical Immunology, Kralovske Vinohrady University Hospital, Prague, Czech Republic
700    1_
$a Racek, Jaroslav $u Institute of Clinical Biochemistry and Haematology, Charles University Medical School and University Hospital, Pilsen, Czech Republic
700    1_
$a Ženková, Jana $u Institute of Clinical Biochemistry and Haematology, Charles University Medical School and University Hospital, Pilsen, Czech Republic $7 xx0207131
700    1_
$a Schneiderka, Petr $u Department of Clinical Biochemistry, Palacky University Hospital, Olomouc, Czech Republic
700    1_
$a Lochman, Pavel $u Department of Clinical Biochemistry, Palacky University Hospital, Olomouc, Czech Republic
700    1_
$a Zima, Tomáš $u Institute of Clinical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Benáková, Hana $u Institute of Clinical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Büchler, Tomáš $u Czech Myeloma Group, Czech Republic; Department of Oncology and 1st Faculty of Medicine, Thomayer University Hospital and Charles University, Prague, Czech Republic
700    1_
$a Spáčilová, Jana $u Institute of Clinical Biochemistry and Diagnostics, Charles University Hospital, Hradec Kralove, Czech Republic
700    1_
$a Hájek, Roman $u Czech Myeloma Group, Czech Republic; Babak Research Institute and Department of Internal Medicine and Hematooncology, Masaryk University Faculty of Medicine and University Hospital, Brno, Czech Republic
700    1_
$a Palička, Vladimír $u Institute of Clinical Biochemistry and Diagnostics, Charles University Hospital, Hradec Kralove, Czech Republic
773    0_
$w MED00010886 $t Clinical chemistry and laboratory medicine CCLM FESCC $x 1434-6621 $g Roč. 49, č. 1 (2011), s. 89-92
856    41
$u https://pubmed.ncbi.nlm.nih.gov/21034251 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m $z 0
990    __
$a 20120817 $b ABA008
991    __
$a 20161013110129 $b ABA008
999    __
$a ok $b bmc $g 949988 $s 785292
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2011 $b 49 $c 1 $d 89-92 $i 1434-6621 $m Clinical chemistry and laboratory medicine $n Clin Chem Lab Med $x MED00010886
GRA    __
$a NS10387 $p MZ0
GRA    __
$a NS10406 $p MZ0
LZP    __
$a Pubmed-20120817/11/03
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace